Rebinyn Approval for Hemophilia B Expanded to Include Routine Prophylaxis
Rebinyn is a recombinant DNA-derived coagulation Factor IX concentrate with an extended half-life.
Rebinyn is a recombinant DNA-derived coagulation Factor IX concentrate with an extended half-life.
Etranacogene dezaparvovec is an investigational gene therapy that uses AAV5 to carry the Padua gene variant of factor IX.
The phase 3 ADVANCE trial evaluated the efficacy and safety of efgartigimod in 131 adults with primary ITP.
Apixaban is a direct oral anticoagulant that relies less on kidney excretion.
But, though difference is small, tranexamic acid not noninferior to placebo for primary safety outcome of composite cardiovascular outcome
In preclinical studies, ASC618 has been shown to have at least a 10-fold increase in the biosynthesis and secretion of FVIII compared with native human FVIII bioengineered constructs.
The phase 3 XTEND-1 study evaluated efanesoctocog alfa in 159 patients with severe hemophilia A who were previously treated with factor VIII replacement therapy.
The Company is currently evaluating asundexian as monotherapy or in combination with antiplatelet therapy in the PACIFIC phase 2 clinical trial program.
Rate of symptomatic intracranial hemorrhage lower with tenecteplase than the current standard medication for thrombolysis, alteplase
Results showed the median ABR for all bleeds was reduced by 54.7%.